2021-09-08 13D Webinar Rough Notes PR: Patent

New Post Public Reply Private Reply Replies (3) Message Board
z_smith01
1,082
2021-09-08 13D Webinar
Rough Notes

PR:
Patent issue
LH
BLA

Detailed plans that will be presented to all in the next few weeks
Not interest in aligning with BP
No communication with BP
Want to develop LL

None of the slate has ownership to IncellDx except Dr. P.

None, including Dr. P, want CYDY to buy IDX

None of proposed nominees have any discussion re: buying IDX

Bought shares in open market, just like “you”

Fed-up with mgmt and just want change.

Stock hit its highs due to Dr. P, including TedTalk
Tried to reunite CYDY and Dr. P
Dr. P had no participation in that endeavor

Sent 8 separate letters to BOD re: inconsistencies re: NP’s statements and SEC filings
No response from CYDY

13D to put CYDY on notice as to grievances
No response from the company

Attempted to avoid a proxy fight
Hoping “beyond hope” to avoid fight

No matter what you think of us
Think drug is fantastic, company is worth saving

Woke up every morning, thinking this is the day we will get approval

All in the same boat – want an approval
That is why they are here today
Shareholders, want the best for the company, want success

New something was wrong with the BLA submission
That mistake alone would cause for change in management

PR was CEO of a NASDAQ listed company
Employed over 1000 employees
Worked with Wall Street
Had independent BOD
Was not fired, replace or removed by the BOD
Left with support of BOD and management
Was paid $425K per year, while profitable
CEO should only be paid, rewarded when producing profits for shareholders

NP was 3rd highest paid CEO in Oregon, WA last year
Only chairman and CEO of Nike was paid more

Chairman of BOD reports to CEO as employee
No chance of NASDAQ approval with this BOD

Why not let shareholders vote?
That was SK’s decision

This proxy fight is about mgmt of CYDY

Is mgmt protecting your investment?

Are you satisfied with their performance?

Compare them to us and make a choice.

Dr. P.
CYDY was $0.26/share
After TedTalk was $10
Thinks he was a part of that SP movement

1st wants to dispel misinformation


Looking forward to his deposition
To say all he is going to say today under oath

Jan 10th, 2020
In Shanghai meeting with Longgen

Jan 27th, tried to get CYDY involved
Way before anyone in US was talking about pathogenesis of COVID

Then sent e-mail to CYDY


Reads e-mail


PR re: working on COVID with China partner



All the info was coming from Bruce

NP wrote e-mail to JL
It has something to do with macrophages

++++

Sign Assignment Agreement
If you invent, it is owned by the University or Employer

Consulting Agreement
If meant anything other than advising the company, it is absurd
It has nothing to do with where we are right now

++++

Went on to talk about dosing
e-mail that showed in a message in Feb
Discussion with Kush
Decided on four doses of LL covering 28 days
b/c of high doses of cytokines they were seeing in the lab
Montifiroe hadn’t even started yet

Other issue was ROT


Had one of the best ROT at IDX
He knew every pt on LL or on placebo



CCR5 expression on immune cells
Dosing is incredibly complex
Can’t throw a dose against wall
CCR5 changes on day-to-day basis
Monocytes, etc.
Level of CCR5 expression varies
The level has to be monitored
Why?
b/c T-regs are “bad” cells, they turn off the immune system, you want to block them 100%
Don’t want to occupy good cells
Can inhibit just the bad cells by appropriate dosing

++++

BLA
Internally, at CYDY there was confusion re: Tropism and ROT
Tropism is on viral side
ROT is on cell/receptor side
ROT has to be measured every day

Were getting confounding results on Tropism assay
CYDY thought ROT could substitute for Tropism

350mg dose is plenty of drug for CD02 b/c on HARRT
Which down-regulates CCR5

FDA wants to be educated, very interested in open dialog
All it required was a meeting with FDA, what are the issues
RTF -- Can guarantee it is not about ROT

Only had ROT on a portion of the MONO trial, which they were using for dose justification on the COMBO trial

Has spreadsheet with MONO
2/3rd of samples and time points didn’t have ROT
It was incomplete
Not that it was bad

IN CD10 and CD12, ROT was working very well


Knew ROT at every sample in COVID trials

Dr. P suggested the 4 doses over 28 days

What is plan for BLA?
Have expert meet with FDA, data in hand, 350mg might be appropriate dose
More is not necessarily better

Appropriate outcome measure should be CD4 count
LL is not an anti-viral

When someone gets flu or similar, their viral load would go up even though drug was working correctly, but that lead to a viral load failure

++++

LH
10,000 pts
Ivermectin is not their primary drug
Drugs are directed at vascular inflammation
Non-classical monocytes carry COVID remnants
Published data already

See 1000 pts a week
Could enroll very quickly

LL + statin is what they would use
Most potent, most successful treatment for LHs known in the world

Discussed outcomes with FDA that they are looking for in LHs

Have 50 clinical sites

Have people reaching out to fund the trial
Would rather do trial with LL than MV

Have some findings on LL that haven’t been released publically yet

Trial could be done very quick

Has no financial obligations to PZ
They (PZ) don’t even know about what he is doing with LHs

++++++

Cancer
LL is not a standalone for cancer
For therapy, must be in combo

Roche doesn’t have PD1

Discusses technical details of other drugs and LL

LL would be a very potent combination with other cancer drugs

+++++

COVID
Critical should be successful
And LHs

DoD is interested in funding trials related to LHs

++++

Showed cover letter
CYDY asked about acquiring IDX
Met with NP and SK
$150M value on cover letter

Only if the company was successful, then it would approach the numbers being thrown around

Didn’t hear even a response from CYDY
That was the beginning of the end

His hope is to get back working with the drug again

LL won’t get a BTD b/c it is in combo with other drugs
And there is no placebo

FDA will not believe the results

+++++

Melissa Yeager
25yrs in exec mgmt
US & int’l regulatory affairs
GILD
BD
Start-ups as well (early as well as late stage development efforts)

Dr. Errico
Long-time shareholder since 2017
Was a CYDY “junkie”
NYU – full tenured professor
Over 35 years in Clinical trials with FDA
Extensive patent experience, over 150 patents
Consultant to one large corp re patents
Founded company sold to Stryker for over $350M
Founded another company, sold around $2.3B
Served on BOD and Comp and Non-Gov committees on NASDAQ company

Chairman reports to CEO
Can’t go on NASDAQ without restructuring

Peter Staats
Founded pain med at JHU
Ran for 10 years
Sold private practice to PE
Cofounded ElectroCore
Was on BOD
Was CMO (left BOD when went as CMO)
Founded approved drug
Served on BOD both private and public
Consultant to FDA
CMO for both private and public companies

Works with wounded warrior
Survivor core as well

Survivor core would be interested in work with us

Investor in CYDY
Wants to lean-in
No history of previous BOD
Just wants to fix it and get stock back up
And most importantly get the drug out there for people who need it.

PR
Attorney
MI legislature
Specialize in insurance and banking law
Started own operation in M&A
Owned private chemical company
Chairman & CEO of NASDAQ company
Chairman of other boards
Chairman of Liquor Control Commission in OR with 800+ employees

TE
The thought that SK refuses to talk to this group – does that fit with his job as head of Biz Dev?


++++++

Q&A

Q: Who owns data for 10k pts? PZ?
A: IDX owns
It is IDX’s cohort
PZ does not own it
It is about partnerships
No one can do it alone
Let’s get the band back together and get this over the finish line

Q: Distinctions on discoveries IDX vs. CYDY?
A: CYDY needs to sign the appropriate agreements.
Master Services Agreement
Lays out who owns the data, samples, IP
There was never one of those agreements signed ever between CYDY and IDX

A consulting agreement is to give them advice

Industry standard contractual relationships – between pharma and other companies

Dr. Sacha was on the patent. That means that OSU owns part of the patent, and he was obligated to assign to INX.

PR:
Dr. P has patents, nationally and int’l that target CCR5
So, take out all the noise
Let’s talk about CYDY’s patent
CYDY has a patent
Usually, the issue is when someone was left off a patent
Dr. P was put on the patent, without his knowledge
They have proof of this, emails
And will put it on the record

He didn’t try to steal it, he was put on it without his knowledge

TE:
I’m going to wear my shareholder hat right now
Appalled that standard agreements were not signed
It is “bush league”

Q: Fife loans outstanding. Yesterday’s 8k filings. Please clarify if it was expected or unexpected conversions?
A:
AW:
Had issue sharing screen
Data is based on SEC reporting
There may be internal company data that would modify the results

8K yesterday was re: shares already on the shelf and being transferred

Potentially “non-diluting” has been used a lot

$10 conversion price was never used in settling the loan with Fife

Fife started in June, 2018

As of 8k yesterday, principal remaining is $57M
$85M paid off debt
$120M paid in cash to note holder (i.e. premium and profit)

$91M profited above the $34M profit above
Therefore, profited about $125M

Jan 19
The terms of the notes were disregarded (conversion and demands)
441% return before selling back into the market

June 29, 2020
Converted 22.5M on this note
4M shares converted

June 30, 2020
Reached all time high to $10

Created side agreements to settle the notes
July 2020 note
Disregarded the demand period

$25M principal
$10 conversion price did not apply at any time to settle the loans

Avg. conversion price was $2.69

S3 was issued to register stock for those loans
Only registered at $10/share
2.8M shares turned into 11.3M shares

S3
2.1M shares at 10 conversion
Same issue

Was asked to wrap it up in interest of time

Will be issuing over 50M shares to settle Fife loans

Could entrench management

Q: Taking company private?
A: No. No plans to take company private.
No connection to BP
Simply shareholders who have huge stake in the financial success of the company
Not taking it over for someone else
Yes, we do want revenue

Q: Why did you cover up past conflicts of interest? Why afraid of giving depositions?
A:
Not afraid of depositions
Just wanted a vote of existing mgmt of 13D group

Q: NP has committed fraud? Going to jail?
A: No idea. No comment. Will cooperate with any investigations.

Q: Why fighting so hard to not take depositions?
A: CYDY brought lawsuit in federal court based on preliminary proxy that we were filling out. Not even a final proxy. When went to court, said they wanted to depose everyone – who gave a penny. They only went to court on preliminary proxy. Bringing suit to make it go away. Spending millions of dollars to make it go away.

The SEC in effect gave approval to go solicit based on the proxies.

They are trying to bankrupt the 13D group.

To NP: Why spending all that money if you are going to win? SK’s decision.

Q: Why would 13D distribute BuyerStrike article?
A: JB has been very vocal against BS or Adam F. or “any of those low lifes”
This group is aligned with long shareholders

NP disclosed they employ 11 different PR firms
Large social media page run by gentleman, who is owner of PR firm paid by CYDY

++++

Wrap-up
Will do more calls

Won’t hear too much from us in the next week or so



3

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Netcapital's 28.62% Plunge: A Fraudulent Drama Unfolds

Updated Category News Views 61

Netcapital: The Plunge Heard 'Round the Market There it is, clear as day—Netcapital’s (NASDAQ: NCPL) stock plummeting 28.62% like a lead balloon. Shareholders had to watch in horror as pieces of their investments seemed to evaporate, all thanks to a swirl of alleged fraud. You can't just shrug off accusations that a company you've betted on has been cooking its books,...

Continue Reading
Landis+Gyr's Big Contract Victory: A Game Changer?

Updated Category News Views 5

Diving into Landis+Gyr's Major Utility Win When news hits about a deal secured by Landis+Gyr Group AG, it rings a few bells across the utility landscape. These folks have brewed up a storm with a fresh contract that slots into their rapidly expanding portfolio of grid-savvy products. So, what’s the fuss about this latest agreement? A Groundbreaking Contract Now, this...

Continue Reading
Artprice Champions Creative Freedom with AI in 2026

Updated Category News Views 96

AI and the Creative Reawakening As the autumn of 2026 rolls in, publishing circles are buzzing over artificial intelligence's role in artistry. Weekly updates hailing rejection, tolerance, or adaptation of AI in writing stir the pot. Yet, Artprice by Artmarket stands out by anchoring creative freedom and responsibility in the spotlight. Grounded on an initiative launched...

Continue Reading
Cognizant & EBRD Unite for Tech Transformation Push

Updated Category News Views 129

An Unexpected Collaboration to Watch Sometimes partnerships come out of left field, like this one between Cognizant and the European Bank for Reconstruction and Development (EBRD). These two are teaming up to inject some serious tech smarts into the Bank's operations over the next five years. What's interesting here is the role AI and automation play in their grand...

Continue Reading
Key Sewer Line Damage Signs Homeowners Often Ignore

Updated Category News Views 37

Spotting Trouble Beneath the Surface Now, when was the last time you eyeballed your home’s plumbing with more than a passing glance? Most folks don’t give their sewer lines two thoughts until something foul pops up. Plumbing expert Jessica Gerdeman from Heggemann, Inc. in Warrenton, Missouri, isn’t just blowing hot air when she points out the indicators of looming...

Continue Reading
CSQR Faces Scrutiny Over Cash Flow Discrepancies

Updated Category News Views 40

Dalrymple's Short Report Shakes Csquare's Core Csquare, Inc. (NYSE: CSQR) is reeling from a one-two punch: a damning short report by Dalrymple Finance and an 11.8% share tumble. The timing of this financial body blow, coinciding with Csquare's discordant cash flow claims, could mark the beginning of a long battle for investor trust. This ain't the first time the markets...

Continue Reading
Keeper Security Shines in Gartner's 2026 PAM Report

Updated Category News Views 92

Recognition That Stands Out When you're in the security game, being flagged in the Gartner® Magic Quadrant™ is like getting the thumbs-up from the industry's toughest critic. Keeper Security just snagged that recognition for the second year straight, and what's putting feathers in their cap? A completeness of vision and the chops to execute—no small feat in the wild...

Continue Reading
MacDonald Steps Up as President at California Bank

Updated Category News Views 0

New Leadership at California Bank & Trust It's a big shakeup in the banking lanes today as Michael MacDonald grabs the helm at California Bank & Trust (CB&T). He's stepping into the President's shoes, bringing along a toolkit of experience and know-how that's tough to find elsewhere. Under his watch, CB&T aims to blend the nimble maneuvering of local banks with the clout...

Continue Reading
PG&E Halts Service; Groups Demand Regulatory Action

Updated Category News Views 62

Pending Storm Over PG&E's Service Delays It's rare that you hear a utility company flat-out say it can't afford to keep the lights on. Yet here we are, staring down the barrel of some unsettling news for 25,000 PG&E customers. They've been warned they might cool their heels for an extra six months before their service is up and running. As if that's not dicey enough, $2...

Continue Reading
Ademi LLP Questions RRC Buyout Deal's Fairness

Updated Category News Views 48

Unease Surrounds RRC's Potential Acquisition by EQT Let’s talk about a messy situation brewing with Range Resources Corporation (NYSE: RRC). The lawyers at Ademi LLP are poking around in the shadows of a proposed buyout by EQT Corporation, questioning whether the deal is legit—or if someone’s getting the short end of the stick. It’s all happening in a climate...

Continue Reading

Top 5 Most Recently Viewed Articles

Financial 15 Split Corp. Plans Normal Course Issuer Bid

Updated Category News Views 108

Announcement of Normal Course Issuer Bid Financial 15 Split Corp. has made a significant announcement regarding its plans to strengthen shareholder value through a Normal Course Issuer Bid (NCIB) following the acceptance by the Toronto Stock Exchange (TSX). This initiative aims to buy back certain classes of shares, primarily focusing on the company's Preferred Shares and...

Continue Reading
NUH Reinvents Healthcare with Green Innovations

Updated Category News Views 42

Award-Winning Green Healthcare from NUH The National University Hospital (NUH) in Singapore is making waves and cleaning the air at the same time. It's racked up a shiny Gold Award at the 2026 International Hospital Federation (IHF) Awards for its Green Operating Theatre programme — and folks, it's not just any old clap on the back. This is low-carbon healthcare in...

Continue Reading
NutraBio Unveils PROTEIN NOW!™: 21g Protein Shot

Updated Category News Views 18

NutraBio Enters the Convenient Protein Arena A hot July day, but my mind's firmly focused on protein. NutraBio Labs, the folks who’ve been pushing nutrition boundaries for over three decades, have rolled out something to shake things up— and I ain't talking about powder shakes. PROTEIN NOW!™ is stepping in with a mighty claim: 21 grams of protein, zero sugar, zero...

Continue Reading
AI and Unified Solutions Revolutionizing Australia’s Workspaces

Updated Category News Views 302

AI and Unified Solutions Transform Australia's Workplaces A dynamic shift is occurring within Australian enterprises as they increasingly adopt artificial intelligence (AI) and advanced analytics. These innovations are successfully integrating into digital workplace solutions, giving companies the edge they need to enhance productivity and remain competitive. Recent...

Continue Reading
WeRide Inc. Sets Price for Initial Public Offering at $15.50

Updated Category News Views 233

WeRide Inc. Pricing Details for Initial Public Offering WeRide Inc. (“WeRide” or the “Company”) (Nasdaq: WRD), a pioneer in the autonomous driving realm, recently revealed the pricing of its initial public offering (IPO). In this offering, the company will issue 7,742,400 American depositary shares (ADSs), where each share represents three of WeRide's Class A...

Continue Reading